Answers are grounded in this paper and cite their sources.
Clinical surveillance reports declining artesunate-mefloquine efficacy in falciparum malaria patients, highlighting the urgent need for containment strategies.
Resistance to many antimalaria drugs developed on the Cambodia-Thailand border long before developing elsewhere. Because antimalaria resistance is now a global problem, artemisinin-based combination therapies (ACTs) are the first-line therapies in most malaria-endemic countries. However, recent clinical and molecular studies suggest the emergence of ACT-resistant Plasmodium falciparum infections in the Cambodia-Thailand border area, where standard ACT is artesunate and mefloquine. These ACT failures might be caused by high-level mefloquine resistance because mefloquine was used for monotherapy long before the introduction of ACT. This observation raises 2 questions. First, how can existing P. falciparum-resistant strains be controlled? Second, how can the evolution of new ACT- resistant strains be avoided elsewhere, e.g., in Africa? Enforcement of rational drug use and improved diagnostic capacity are among the measures needed to avoid and contain ACT resistance.
No takes yet. Share an insight, caveat, or question.
Wongsrichanalai et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: